Release Summary

Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE, a Phase 2b clinical trial of VT-1161 for treatment of recurrent vulvovaginal candidiasis, RVVC.

Viamet Pharmaceuticals, Inc.